Novo Nordisk to Discontinue Levemir in 2024

Upgrade to Patent-Protected Tresiba — or else!On Wednesday, November 8, 2023, Novo Nordisk announced that it would discontinue its long-acting insulin Levemir (insulin detemir injection) in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The company ' s official statement (seehttps://www.novomedlink.com/diabetes/products/treatments/levemir.html) said: " We will continue to provide Levemir FlexPen and Levemir vials to wholesalers while supplies last, up to the discontinuation dates, but supply disruptions should be expected. "It added further: " Levemir FlexPen, the injection pen version of insulin detemir, will likely face supply disruption starting in mid-January 2024, lasting up until the FlexPen ' s discontinuation on April 1. Levemir in vial form will no longer be available after Dec. 31, 2024. " The company also warned of imminent supply chain issues. " Discontinuing Levemir was the result of thoughtful deliberation " , according to the statement. That line of bullshit I ' ve heard previously from Novo Nordisk.What it " deliberated " was to ask whether can it deploy an old tactic of forced upgrades following discontinuation of a product? The answer to that may not be yes as of 2023. I recall when Novo Nordisk originally discontinued Novolin L(ente). The good news for me was that at the time, Lilly still made that product for about a year or two after Novo pulled the plug on it, so I just switch...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 basal insulin diatribe discontinue insulin detemir Levemir Novo Nordisk Source Type: blogs